^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | tinengotinib (TT-00420) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Excerpt:
...- Cohort B: other FGFR alterations, including FGFR2 mutations and FGFR1/3 alterations, including fusions...
Trial ID:
Source:
Title:
Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis
Published date:
01/17/2023
Excerpt:
Eligible patients (pts) with advanced/metastatic CCA exhausting standard treatment options received tinengotinib 10 mg QD….Overall DCR (CR or PR+SD) was 90% (9/10) in FGFR2 fusion/rearrangement pts; 100% in FGFR primary mutation pt (1/1)....The preliminary biomarker analysis suggests loss of resistant FGFR mutation on liquid biopsy post tinengotinib therapy....Tinengotinib may result in promising clinical benefit for CCA pts in the setting of FGFRi-resistance.
DOI:
10.1200/JCO.2023.41.3_suppl.539
Trial ID:
Source:
Title:
P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma
Published date:
07/04/2021
Excerpt:
Among the 9 patients CCA patients enrolled, 8 (88.9%) had intrahepatic CCA and 7 (77.8%) had an FGFR2 alteration….Out of 5 evaluable patients with an FGFR2 alteration, 2 achieved a confirmed partial response (PR).
DOI:
10.1016/j.annonc.2021.05.315
Trial ID:
